Literature DB >> 3443146

Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.

G F Peart1, J Boutagy, G M Shenfield.   

Abstract

The oxidative metabolism of tolbutamide was studied in 13 healthy subjects of known debrisoquine phenotype. Three were poor (PM) and ten were extensive (EM) metabolisers of debrisoquine. The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1. kg-1 in PM subjects and 0.22 ml.min-1.kg-1, 4.3 h and 0.15 ml.min-1.kg-1 in EM subjects. Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects. There were no statistically significant differences between EM and PM metabolisers for any of these parameters. In addition there was no correlation between the debrisoquine metabolic ratio and tolbutamide urinary metabolite recovery or plasma clearance. These data indicate that hydroxylation of debrisoquine and tolbutamide are not catalyzed by the same enzyme. The ratio of hydroxy- to carboxytolbutamide in our subjects, and in other recent studies, suggests that some previous publications were inaccurate and their conclusions about the genetic control of tolbutamide metabolism were incorrect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443146     DOI: 10.1007/BF00637637

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  Drug absorption, metabolism, and excretion. IX. Some new aspects of pharmacokinetics on tolbutamide in rabbits.

Authors:  J Shibasaki; R Konishi; T Morishita; T Ueki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1973-08       Impact factor: 1.645

Review 3.  Ethnic differences in reactions to drugs and xenobiotics. Therapy.

Authors:  D A Evans
Journal:  Prog Clin Biol Res       Date:  1986

4.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

5.  The metabolic fate of tolbutamide in man and in the rat.

Authors:  R C Thomas; G J Ikeda
Journal:  J Med Chem       Date:  1966-07       Impact factor: 7.446

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.

Authors:  J O Miners; L M Wing; D J Birkett
Journal:  Aust N Z J Med       Date:  1985-06

8.  Debrisoquine oxidation in an Australian population.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

9.  Pharmacogenetics of tolbutamide metabolism in humans.

Authors:  J Scott; P L Poffenbarger
Journal:  Diabetes       Date:  1979-01       Impact factor: 9.461

Review 10.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

View more
  6 in total

1.  Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.

Authors:  S Kanamitsu; K Ito; Y Sugiyama
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

2.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 3.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  A screening test for slow metabolisers of tolbutamide.

Authors:  M A Page; J S Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

5.  The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.

Authors:  R E Ferner; M L Antsiferov; A W Kelman; K G Alberti; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.